Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer [version 1; peer review: 2 approved]
Breast cancer is a global health issue. For decades, breast cancer was classified into many histological subtypes on the basis of microscopic and immunohistochemical evaluation. The discovery of many key genomic driver events involved in breast cancer carcinogenesis resulted in a better understandin...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2019-04-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/8-591/v1 |
| _version_ | 1819297672968798208 |
|---|---|
| author | Georges El Hachem Andrea Gombos Ahmad Awada |
| author_facet | Georges El Hachem Andrea Gombos Ahmad Awada |
| author_sort | Georges El Hachem |
| collection | DOAJ |
| description | Breast cancer is a global health issue. For decades, breast cancer was classified into many histological subtypes on the basis of microscopic and immunohistochemical evaluation. The discovery of many key genomic driver events involved in breast cancer carcinogenesis resulted in a better understanding of the tumor biology, the disease heterogeneity and the prognosis leading to the discovery of new modalities of targeted therapies and opening horizons toward a more personalized medicine. In recent years, many therapeutic options emerged in the field of metastatic breast carcinoma, especially for the luminal subtypes. They were able to transform the course of the disease while maintaining quality of life. However, the options are still limited for triple-negative breast cancer, but the better knowledge of its complex biology and the discovery of molecular targets are promising for more efficient novel therapies. |
| first_indexed | 2024-12-24T05:17:44Z |
| format | Article |
| id | doaj.art-4ba124caeea54913b82518eb4fcefeb2 |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-24T05:17:44Z |
| publishDate | 2019-04-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-4ba124caeea54913b82518eb4fcefeb22022-12-21T17:13:32ZengF1000 Research LtdF1000Research2046-14022019-04-01810.12688/f1000research.17542.119184Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer [version 1; peer review: 2 approved]Georges El Hachem0Andrea Gombos1Ahmad Awada2Department of Hematology and Medical Oncology, Saint George Hospital University Medical Center, University of Balamand, Beirut, LebanonOncology Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, BelgiumOncology Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, BelgiumBreast cancer is a global health issue. For decades, breast cancer was classified into many histological subtypes on the basis of microscopic and immunohistochemical evaluation. The discovery of many key genomic driver events involved in breast cancer carcinogenesis resulted in a better understanding of the tumor biology, the disease heterogeneity and the prognosis leading to the discovery of new modalities of targeted therapies and opening horizons toward a more personalized medicine. In recent years, many therapeutic options emerged in the field of metastatic breast carcinoma, especially for the luminal subtypes. They were able to transform the course of the disease while maintaining quality of life. However, the options are still limited for triple-negative breast cancer, but the better knowledge of its complex biology and the discovery of molecular targets are promising for more efficient novel therapies.https://f1000research.com/articles/8-591/v1 |
| spellingShingle | Georges El Hachem Andrea Gombos Ahmad Awada Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer [version 1; peer review: 2 approved] F1000Research |
| title | Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer [version 1; peer review: 2 approved] |
| title_full | Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer [version 1; peer review: 2 approved] |
| title_fullStr | Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer [version 1; peer review: 2 approved] |
| title_full_unstemmed | Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer [version 1; peer review: 2 approved] |
| title_short | Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer [version 1; peer review: 2 approved] |
| title_sort | recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple negative breast cancer version 1 peer review 2 approved |
| url | https://f1000research.com/articles/8-591/v1 |
| work_keys_str_mv | AT georgeselhachem recentadvancesinunderstandingbreastcancerandemergingtherapieswithafocusonluminalandtriplenegativebreastcancerversion1peerreview2approved AT andreagombos recentadvancesinunderstandingbreastcancerandemergingtherapieswithafocusonluminalandtriplenegativebreastcancerversion1peerreview2approved AT ahmadawada recentadvancesinunderstandingbreastcancerandemergingtherapieswithafocusonluminalandtriplenegativebreastcancerversion1peerreview2approved |